Spyre Therapeutics director receives 63,227 shares

Spyre Therapeutics, Inc. director Michael Thomas Henderson reported receiving 63,227 shares of common stock on January 21, 2026.

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. director Michael Thomas Henderson reported receiving 63,227 shares of common stock on January 21, 2026. The shares were received for no cash consideration through a pro-rata distribution from a limited liability company in which he is a member, rather than through an open-market purchase. Following this distribution, he beneficially owns 168,606 shares of Spyre Therapeutics common stock in direct form.

Insider Trade Summary

Other: 63,227 shares

Other 1 txn

Insider HENDERSON MICHAEL THOMAS

Role Director

Type	Security	Shares	Price	Value
Other	Common Stock	63,227	$0.00	$0.00

Holdings After Transaction: Common Stock — 168,606 shares (Direct)

Footnotes (1)

1. F1. Represents the pro-rata distribution of shares of common stock for no consideration from a limited liability company in which the Reporting Person is a member.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SYRE director Michael Thomas Henderson report?

Director Michael Thomas Henderson reported acquiring 63,227 shares of Spyre Therapeutics, Inc. (SYRE) common stock on January 21, 2026.

At what price were the Spyre Therapeutics (SYRE) shares acquired in this Form 4?

The 63,227 shares of Spyre Therapeutics common stock were reported at a price of $0.00 per share, reflecting that no cash was paid in the transaction.

What is the source of the 63,227 SYRE shares reported in this insider filing?

The 63,227 shares represent a pro-rata distribution of common stock made for no consideration from a limited liability company in which the reporting person is a member.

How many Spyre Therapeutics (SYRE) shares does Michael Thomas Henderson own after the transaction?

After the reported transaction, Michael Thomas Henderson beneficially owns 168,606 shares of Spyre Therapeutics common stock directly.

Was this Spyre Therapeutics (SYRE) insider transaction a market purchase or sale?

No cash purchase or sale was reported. The 63,227 shares were received via a pro-rata distribution from an LLC, not through an open-market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/23/2026 - 09:31 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENDERSON MICHAEL THOMAS

(Last) (First) (Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		J(1)		63,227	A	$0	168,606	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the pro-rata distribution of shares of common stock for no consideration from a limited liability company in which the Reporting Person is a member.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.